IP Library Granted Patent US 8,728,533
Granted Patent B2
US 8,728,533 · App. 13/728,508 · Granted May 20, 2014

Composition comprising crustacean gastrolith components and its use

Inventors: Yossi Ben (D.N. Arava, IL); Amir Sagi (Omer, IL)
Assignees: Yossi Ben; Ben-Gurion University of the Negev Research and Development Authority
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,533
App. No.
13/728,508
Granted
May 20, 2014
Kind
B2
Abstract

Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consists of chitin and polypeptide. The formulation is efficient in treating various pathological conditions, including proliferative diseases, neurological disorders, and musculoskeletal disorders.

Claims (33)

1. A method for treating breast carcinoma comprising orally administering a pharmaceutical composition consisting of

(A) dried, ground crustacean gastrolith having

(i) 100 weight parts (wp) of calcium carbonate finely mixed with

(ii) from 10 to 30 wp of organic matter having

(a) from 90 to 99 wt % chitin and

(b) from 1 to 10 wt % polypeptide,

(iii) up to 30 wp of moisture per 100 wp of calcium carbonate, and

(iv) up to 40 wp of inorganic salts other than calcium carbonate, and

(B) a pharmaceutical carrier, a pharmaceutical binding agent, or a pharmaceutical diluent.

2. The method according to claim 1 , wherein said inorganic salts are selected from the group consisting of magnesium, potassium, strontium, sodium, phosphate, sulfate, chloride, bromide, and fluoride.

3. The method according to claim 1 , wherein the calcium carbonate in said composition is amorphous.

4. The method according to claim 1 , wherein said breast carcinoma further comprises metastasis in other organs.

5. The method according to claim 4 , wherein said metastasis is bone metastasis.

6. The method according to claim 1 , wherein said treating comprises shrinking tumors, stopping their growth, or slowing down or inhibiting the cell proliferation in a tumor.

7. The method according to claim 1 , wherein said treating further comprises alleviating pain associated with said breast carcinoma.

8. The method according to claim 1 , wherein said composition is administered orally in daily doses of from about 0.5 to about 3 g.

9. The method according to claim 1 , wherein said composition is in the form of a tablet.

10. A method for treating breast carcinoma comprising orally administering a pharmaceutical composition consisting of

(A) dried, ground crustacean gastrolith having

(i) 100 weight parts (wp) of calcium carbonate finely mixed with

(ii) from 10 to 30 wp of organic matter having

(a) from 90 to 99 wt % chitin and

(b) from 1 to 10 wt % polypeptide,

(iii) up to 30 wp of moisture per 100 wp of calcium carbonate, and

(iv) up to 40 wp of inorganic salts other than calcium carbonate.

11. The method according to claim 10 , wherein said inorganic salts are selected from the group consisting of magnesium, potassium, strontium, sodium, phosphate, sulfate, chloride, bromide, and fluoride.

12. The method according to claim 10 , wherein the calcium carbonate in said composition is amorphous.

13. The method according to claim 10 , wherein said breast carcinoma further comprises metastasis in other organs.

14. The method according to claim 13 , wherein said metastasis is bone metastasis.

15. The method according to claim 10 , wherein said treating comprises shrinking tumors, stopping their growth, or slowing down or inhibiting the cell proliferation in a tumor.

16. The method according to claim 10 , wherein said treating further comprises alleviating pain associated with said breast carcinoma.

17. The method according to claim 10 , wherein said composition is administered orally in daily doses of from about 0.5 to about 3 g.

18. The method according to claim 10 , wherein said composition is in the form of a tablet.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2014
From: BEN, YOSSI; SAGI, AMIR
To: BEN, YOSSI; BEN-GURION UNIVERSITY OF THE NEGEV AND DEVELOPMENT AUTHORITY
Reel/Frame 032199/0648 →
Priority Claims (1)
IL 178495 · Oct 5, 2006 · national
Continuity (2)
Continuation 12443987
Related Publication 20130122117A1 · May 16, 2013